RxDoctor Payments Data

Mary Nobles

Nurse Practitioner · Atlanta, GANPI 1255881363

Payments from drug & device makers

$593in general payments, 2019–2025

Across 18 payments — averaging $32.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$157
  • Johnson & Johnson$145
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$95
  • Abbott$83
  • Merck$35
  • Boston Scientific$32
  • plus $45 from 3 others

What the payments were for

  • Food & beverage$47580%
  • Education$11820%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$593 in reported general payments places this provider in the 65th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$21,344
Medicare patients
100
Services billed
219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban76$89,589
XareltoRivaroxaban19$22,772
Repatha SureclickEvolocumab24$15,829
Nebivolol Hcl33$2,524
Metoprolol Succinate127$1,929
Atorvastatin Calcium122$1,376
Potassium Chloride78$1,100
Carvedilol116$1,008
Ezetimibe39$857
Ranolazine ErRanolazine13$786
Amlodipine Besylate166$719
Losartan Potassium71$665
Hydralazine Hcl55$626
Hydrochlorothiazide74$567
Lisinopril84$551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$89,58976 claims
Johnson & JohnsonXarelto$145$22,77219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →